The short answer
Yohimbine can oppose clonidine’s blood-pressure effect. A controlled experiment in healthy volunteers found that yohimbine reversed the fall in systolic pressure caused by clonidine. This supports a real pharmacologic concern, although it does not show that clonidine absorption is reduced.
What this answer covers
Oral purified yohimbine with oral immediate-release clonidine, both studied as hydrochloride salts. Acute volunteer results do not define a safe dose for chronic treatment.
- Supplement or preparation
- yohimbine
- Medication ingredient
- clonidine
What is the interaction?
The two substances can have opposing effects on the body’s adrenergic signaling. In the direct experiment, yohimbine reversed several clonidine effects, including lower systolic pressure and reduced alertness. The finding concerns their actions, not a demonstrated loss of drug absorption.
How much does the study tell us?
The study compared single doses, their combination and placebo in healthy volunteers. It gives direct evidence for acute opposition, but does not quantify long-term blood-pressure control in people with hypertension. Its doses are research details, not a regimen to try.
Is yohimbe bark equivalent?
A bark product may contain yohimbine, but its amount can be variable or inaccurately labeled. A known-dose purified substance and an unspecified supplement are not equivalent. The product should be reviewed even when the label presents it only as an herb.
Can spacing solve the problem?
The study did not establish a spacing interval that avoids the opposing effects. Speak with your prescriber before taking yohimbine with clonidine. Do not increase or abruptly stop clonidine to compensate for the supplement.
Evidence and practical considerations
Physiologic interactions
Direct acute human coadministration supports antagonism of clonidine’s systolic-pressure effect by purified yohimbine. Reduced absorption was not measured.
- Exact scope
- Oral purified yohimbine with oral immediate-release clonidine, both studied as hydrochloride salts. Acute volunteer results do not define a safe dose for chronic treatment. with Clonidine, RxCUI 2599, IN. The inspected oral immediate-release clonidine hydrochloride label explicitly identifies its clonidine free-base equivalent. That salt-to-active-ingredient bridge is restricted to the labeled oral formulation; patch, epidural and extended-release regimens are not assigned the same exposure automatically.
- Medication form and route
- oral
What remains uncertain
- Small acute healthy-volunteer experiment; no long-term or botanical dose equivalence.
Factors that may matter: exact product and dose; baseline blood pressure; other medicines.
Read the supporting source summaries
Source 1: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy volunteers in a double-blind crossover experiment.
Yohimbine reversed the clonidine-associated systolic-pressure reduction, reduced alertness and prolonged light-reflex recovery.
How this applies: Direct acute coadministration of the named active ingredients as hydrochloride salts. Applying the measured yohimbine exposure to bark products requires a content qualification.
Original abstract inspected. No long-term hypertension outcomes, product-specific bark doses, or clonidine absorption measurements. The abstract does not explicitly state the administration route; full-text methods still require verification before clinical publication.
Source 2: government botanical reference
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering yohimbe supplements.
Identifies blood-pressure and other serious safety concerns; the amount of yohimbine can vary and labeling may be inaccurate.
How this applies: Purified yohimbine and variable-content bark supplements are different exposures; no bark dose is inferred from the acute trial.
General botanical safety reference rather than a controlled clonidine interaction trial.
Source 3: regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release clonidine.
Describes blood-pressure lowering, sedation, interactions with other sedating drugs, and potentially severe rebound hypertension after abrupt withdrawal.
How this applies: Defines medication context and prevents an unsupported recommendation to stop clonidine.
Does not directly test the botanical combinations in this batch. The free-base bridge is explicit in Description.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original article drafted after source checks. Exact preparation, route, contrary evidence and claim limitations recorded for review. | |
| Research summary published |
Article revision: 8c55a63f22e73b09
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.